Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
214 hedge funds and large institutions have $2.7B invested in Global Blood Therapeutics, Inc. in 2021 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 97 reducing their positions, and 39 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $2.79B → $2.7B (-$86.5M)
6% less funds holding
Funds holding: 228 → 214 (-14)
12% less call options, than puts
Call options by funds: $19.8M | Put options by funds: $22.6M
33% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 39
36% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 97
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$106M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$58.5M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$40.7M |
| 4 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$36.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$33.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$68.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$28.3M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$25.8M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$23.9M |
| 5 |
Goldman Sachs
New York
|
-$19.7M |
GBT Hedge Fund Activity: Q1 2021 in Review
214 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2021, worth a combined $2.7B — down 3.1% from $2.79B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of GBT and 26 opened new positions — a net loss of 13 holders — while 97 trimmed existing stakes and 62 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $106M. The largest seller was Fidelity Investments, cutting an estimated $68.8M.
- 214 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2021, down from 228 in Q4 2020.
- Funds reported $2.7B of Global Blood Therapeutics, Inc. stock for Q1 2021, down 3.1% quarter-over-quarter.
- 26 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2021 and 39 closed out, a net change of -13 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2021 was Baker Bros. Advisors, an estimated $106M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2021 was Fidelity Investments, an estimated $68.8M sold.
Based on aggregated 13F filings for Q1 2021.